Introduction Of A Combined OST/Advanced Fibrosis Community Clinic Results In High Engagement With A Cohort Of Patients With Previous Non Attendance At Hospital Appointments.

Background: Direct acting antivirals (DAAs) make community treatment easier. In Glasgow, patients with F0-2 disease may be treated by nurses in the community following MDT discussion. However those with F3/4 disease require consultant review. Hospital attendance rates are historically poor. We initiated a pilot community advanced fibrosis clinic to attempt to engage such patients in care. Description of model of care/intervention: Patients with HCV on opiate substitution therapy (OST) were offered care in a combined Addictions/HCV outreach clinic. Following education and liver assessment including fibroscan, by the liver nurse specialist (LNS), those with F0/2 disease eligible for interferon free treatment proceeded to treatment. Those with F3/4 disease, or only eligible for Interferon therapy, were seen in a monthly consultant outreach clinic (all patients are now eligible for DAAs). Prescription management aligned appointments to see the LNS and consultant with addictions review and OST prescription. Effectiveness: From November 2016 to April 2018, 64 patients underwent assessment: 36 (56%) F0-2, 7 (11%) F3, 21 (33%) F4 including 6 with decompensation (4 CPB, 2 CPC). Median time from diagnosis was 7(±6) years. 16 (25%) were drinking to excess, 16 (25%) reported current injecting drug use, 35 (55%) reported ongoing non-injecting drug use. Prior to referral to the consultant outreach clinic, patients had failed to attend 220 HCV related hospital based appointments (100 consultant, 120 nurse, median 4 missed appointments per patient). 53/56 (95%) patients requiring consultant review attended. To date 48/64 (75%) have started treatment. 27 patients have completed treatment, and to date 19/19 have achieved SVR12. Conclusion and next steps: A dedicated combined addictions/hepatology advanced fibrosis outreach clinic demonstrated high attendance rates. This approach allowed for hepatology review and management of a cohort with a high burden of advanced/decompensated liver disease, with previous nonattendance at multiple hospital appointments. Disclosure of Interest Statement: Dr Barclay has received grants, advisory board and speakers fees from Abbvie and Gilead, and speakers fees from MSD. Note: If accepted into the programme you will be requested to include a disclosure of interest slide into your presentation or include such statements in your poster.

Download abstract Download Poster